Comparison of hk2, pro-hk2 Failure With Conventional PSA Failure in Permanent Brachytherapy and External Beam Prostate Cancer Patients in a Prospective Biomarker Protocol

Author(s):  
B.J. Davis ◽  
G.G. Klee ◽  
D.W. Hillman ◽  
X. Zhao ◽  
L.A. Mynderse ◽  
...  
Brachytherapy ◽  
2016 ◽  
Vol 15 ◽  
pp. S198-S199
Author(s):  
Elisabeth Arrojo ◽  
Esther Garcia Diaz ◽  
Pedro J. Prada Gomez ◽  
Beatriz Suarez Baena ◽  
Michael Ghilezan ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-16 ◽  
Author(s):  
Saskia M. Camps ◽  
Davide Fontanarosa ◽  
Peter H. N. de With ◽  
Frank Verhaegen ◽  
Ben G. L. Vanneste

External beam radiotherapy (EBRT) is one of the curative treatment options for prostate cancer patients. The aim of this treatment option is to irradiate tumor tissue, while sparing normal tissue as much as possible. Frequent imaging during the course of the treatment (image guided radiotherapy) allows for determination of the location and shape of the prostate (target) and of the organs at risk. This information is used to increase accuracy in radiation dose delivery resulting in better tumor control and lower toxicity. Ultrasound imaging is harmless for the patient, it is cost-effective, and it allows for real-time volumetric organ tracking. For these reasons, it is an ideal technique for image guidance during EBRT workflows. Review papers have been published in which the use of ultrasound imaging in EBRT workflows for different cancer sites (prostate, breast, etc.) was extensively covered. This new review paper aims at providing the readers with an update on the current status for prostate cancer ultrasound guided EBRT treatments.


2011 ◽  
Vol 99 ◽  
pp. S382
Author(s):  
B. Smolska-Ciszewska ◽  
G. Plewicki ◽  
M. Giglok ◽  
K. Behrendt ◽  
M. Gawkowska-Suwinska ◽  
...  

1997 ◽  
Vol 15 (4) ◽  
pp. 1465-1469 ◽  
Author(s):  
A V D'Amico ◽  
R Whittington ◽  
S B Malkowicz ◽  
D Schultz ◽  
J E Tomaszewski ◽  
...  

PURPOSE A multivariable analysis to evaluate the potential clinical and pathologic factors that predict for early biochemical failure in patients with pathologically organ-confined and margin-negative disease was performed to define patients who may benefit from adjuvant therapy. PATIENTS AND METHODS Three hundred forty-one prostate cancer patients treated with a radical retropubic prostatectomy between January 1989 and June 1995 and found to have pathologically organ-confined and margin-negative disease comprised the study population. A logistic regression multivariable analysis to evaluate the predictive value of the preoperative prostate-specific antigen (PSA) level, pathologic (prostatectomy) Gleason score, and pathologic stage on PSA failure occurring during the first postoperative year was performed. RESULTS Predictors of PSA failure during the first postoperative year in patients with pathologically organ-confined disease included pathologic Gleason score > or = 7 (P = .0007) and preoperative PSA level greater than 10 (P < .0001). Corresponding 3-year freedom-from-PSA-failure rates for these pathologic organ-confined patients with both, one, or neither of these factors were 60%, 75% to 84%, and 95%, respectively (P < .0001). CONCLUSION Prostate cancer patients with pathologically organ-confined and margin-negative disease and a preoperative PSA level greater than 10 ng/mL or a pathologic Gleason score > or = 7 have significant decrements in short-term PSA-failure-free survival. Therefore, these patients should be considered for adjuvant therapy in the setting of a phase III clinical trial.


Sign in / Sign up

Export Citation Format

Share Document